Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

131.60 -1.68 (-1.26%)
Official Closing Price Updated: 4:10 PM EDT, Jul 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,647,638
Open 132.50
Bid (Size) 131.51 (1)
Ask (Size) 131.74 (1)
Prev. Close 133.28
Today's Range 130.92 - 132.90
52wk Range 77.95 - 148.15
Shares Outstanding N/A
Dividend Yield 1.34%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Fabulous Growth Stocks to Buy and Hold Forever
The bull market in growth stocks is more than just chipmakers if investors will only widen their lens to see the opportunities available. 
Via InvestorPlace
UK's NHS Prescribes Weight-Loss Drug Wegovy Less Than Expected Due To Service Shortages
The NHS has prescribed Wegovy far less often than expected due to a shortage of weight management clinics, highlighting significant challenges in meeting growing demand for the weight-loss drug. 
Via Benzinga

Performance

YTD
+28.88%
+28.88%
1 Month
-7.51%
-7.51%
3 Month
+2.30%
+2.30%
6 Month
+24.89%
+24.89%
1 Year
+62.40%
+62.40%

More News

Read More
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
Via Benzinga
3 Stocks to Buy if There Is No Interest Rate Cut This Year
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Insulin Device Maker Embecta Weighs Sale After 70% Share Decline Following Becton Dickinson Spin-Off
Via Benzinga
Novo Nordisk Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Britain's Drug Regulator Approves Novo Nordisk's Weight Loss Drug Wegovy To Cut Heart Disease Risk In Obese Patients
Via Benzinga
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
Via The Motley Fool
Why Hims & Hers Heath Shares Are Surging Today
Via Benzinga
Biden's Exit From Presidential Race 'Yet Another Curveball For Equity Investors': Analysts
Via Benzinga
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
Via Benzinga
7 Sorry Biotech Stocks Set to Make Investors Sad
Via InvestorPlace
Here's My Top Growth Stock to Buy Right Now
Via The Motley Fool
3 Monster Stocks in the Making to Buy Right Now
Via The Motley Fool
Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications
Via Benzinga
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
Via Investor's Business Daily
Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval
Via Benzinga
7 A-Rated Stock Picks With Huge Upside Potential
Via InvestorPlace
Is Viking Therapeutics a Millionaire-Maker?
Via The Motley Fool
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
Via Benzinga
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
Via Benzinga
Topics Stocks
Exposures US Equities
AI Demand and New Deals Make Ginkgo Bioworks Stock a Speculative Buy
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Forget Boring Diversification! 3 Wild-Card Stocks to Spice Up Your Portfolio
Via InvestorPlace
Novo Nordisk Faces Setback in Netherlands Over Wegovy Insurance Coverage
Via Benzinga
Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.